10.45
+0.83(+8.63%)
Currency In USD
| Previous Close | 9.62 |
| Open | 9.76 |
| Day High | 10.63 |
| Day Low | 9.74 |
| 52-Week High | 34.87 |
| 52-Week Low | 9.25 |
| Volume | 1.28M |
| Average Volume | 2.82M |
| Market Cap | 1.06B |
| PE | -1.92 |
| EPS | -5.45 |
| Moving Average 50 Days | 12.35 |
| Moving Average 200 Days | 19.51 |
| Change | 0.83 |
If you invested $1000 in Intellia Therapeutics, Inc. (NTLA) since IPO date, it would be worth $472.85 as of February 05, 2025 at a share price of $10.45. Whereas If you bought $1000 worth of Intellia Therapeutics, Inc. (NTLA) shares 5 years ago, it would be worth $715.75 as of February 05, 2025 at a share price of $10.45.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema
GlobeNewswire Inc.
Jan 22, 2025 12:30 PM GMT
CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient has been
Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)
GlobeNewswire Inc.
Jan 09, 2025 9:00 PM GMT
Priority programs – NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis – set foundation for significant, near-term value creation Phase 3 HAELO study evaluating NTLA-2002 for HAE to complet
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
GlobeNewswire Inc.
Nov 25, 2024 12:30 PM GMT
CAMBRIDGE, Mass, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug